A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity

Exclusion Criteria

• •1. History of allergy to any component of the experimental drugs.
• •2. Previous use of any botulinum toxin within 6 months prior to enrollment, or plan to use other botulinum toxins not specified in the study protocol during the study.
• •3. Fixed contractures of the studied limb.
• •4. Any medical condition that may increase the risk to the subject when using botulinum toxin type A.
• •5. Need for treatment with drugs that interfere with neuromuscular function during the study.
• •6. Plan or anticipate to use new antispasticity drugs during the study.
• •7. History of epilepsy.
• •8. Pregnant or breastfeeding women.
• •9. Participation in other drug/device clinical trials within 1 month prior to enrollment.